Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41392-020-00213-8 http://scihub22266oqcxt.onion/10.1038/s41392-020-00213-8 32616710!7331117!32616710     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Signal+Transduct+Target+Ther 2020 ; 5 (1): 113 Nephropedia Template TP {{tp|p=32616710|t=2020. Overcoming cancer therapeutic bottleneck by drug repurposing |pdf=|usr=}}{{32616710}} gab.com Text Overcoming cancer therapeutic bottleneck by drug repurposing JO: Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=32616710 #FOAvip Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The "treasure trove" of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono- or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake. Twit Text FOAVip Overcoming cancer therapeutic bottleneck by drug repurposing ????Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=32616710 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32616710 #FOAvip English Wikipedia <ref>{{Cite pmid|32616710}}</ref> Overcoming cancer therapeutic bottleneck by drug repurposing #MMPMID32616710 Zhang Z; Zhou L; Xie N; Nice EC; Zhang T; Cui Y; Huang C Signal Transduct Target Ther 2020[Jul]; 5 (1): 113 PMID32616710show ga Ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing, the development of old drugs for new therapeutic purposes. This strategy with a cost-effective way offers a rare opportunity for the treatment of human neoplastic disease, facilitating rapid clinical translation. With an increased understanding of the hallmarks of cancer and the development of various data-driven approaches, drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target-defined antineoplastic compounds. The "treasure trove" of non-oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer. Indeed, different from targeted drugs, these old generic drugs, usually used in a multi-target strategy may bring benefit to patients. In this review, aiming to demonstrate the full potential of drug repurposing, we present various promising repurposed non-oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono- or drug combination therapy. We also summarize approaches used for drug repurposing and discuss the main barriers to its uptake. |*Drug Discovery[MESH] |*Drug Repositioning[MESH] |Antineoplastic Agents/*therapeutic use[MESH] |Humans[MESH]Overcoming cancer therapeutic bottleneck by drug repurposing (epmc).pdf DeepDyve Pubget Overpricing